in Newswire April 14, 2021

CytoDyn Hit with Securities Class Action Over Alleged ‘Hyping’ of HIV Therapy as Potential COVID-19 Treatment

by Corrado Rizzi

Last Updated on April 14, 2021

Goodwin v. CytoDyn, Inc. et al.

Filed: April 9, 2021 § 3:21-cv-05260

CytoDyn and its CEO and CFO face a class action over what investors call the biotech company’s “aggressive” hyping of its potential HIV therapy Leronlimab as a possible treatment for COVID-19.

Defendant(s)

CytoDyn, Inc.

State(s)

Washington

Last Updated on April 14, 2021 — 8:04 AM

Corrado Rizzi

corrado@classaction.org

Corrado Rizzi is the Managing Editor and a writer for ClassAction.org.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.